aTyr Pharma/LIFE

$1.74

3.57%
-
1D1W1MYTD1YMAX

About aTyr Pharma

aTyr Pharma, Inc. is a clinical-stage biotechnology company. The Company is leveraging intelligence to translate tRNA synthetase biology into new therapies for fibrosis and inflammation. Its lead therapeutic candidate is efzofitimod, a biologic immunomodulator in clinical development for the treatment of interstitial lung disease (ILD), a group of immune-mediated disorders that can cause inflammation and fibrosis, or scarring, of the lungs. Efzofitimod is a tRNA synthetase derived therapy that selectively modulates activated myeloid cells through neuropilin-2 (NRP2) to resolve aberrant inflammation without immune suppression and prevent the progression of fibrosis. ATYR0101 is a fusion protein derived from a domain of aspartyl-tRNA synthetase (DARS). ATYR0101 binds directly to latent-transforming growth factor beta-binding protein 1 (LTBP1), which regulates transforming growth factor beta (TGFb). Its ATYR0750 is a fusion protein derived from a domain of alanyl-tRNA synthetase (AARS).

Ticker

LIFE

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Sanjay Shukla

Employees

56

Headquarters

San diego, United States

aTyr Pharma Metrics

BasicAdvanced
$124M
Market cap
-
P/E ratio
-$0.90
EPS
1.20
Beta
-
Dividend rate
$124M
1.19782
$2.45
$1.08
559K
6.065
1.536
2.136
-43.13%
-55.5%
-48.85%
210.084
1.449
1.462
-94.34%
37.65%
-67.68%

What the Analysts think about aTyr Pharma

Analyst Ratings

Majority rating from 5 analysts.
Buy

Price Targets

Average projection from 5 analysts.
1,313.79% upside
High $35.00
Low $16.00
$1.74
Current price
$24.60
Average price target

aTyr Pharma Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-7,700% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$200K
∞%
Net income
-$15M
4.76%
Profit margin
-7,700%
-∞%

aTyr Pharma Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 2.54%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.22
-$0.20
-$0.25
-$0.23
-
Expected
-$0.28
-$0.23
-$0.24
-$0.24
-$0.23
Surprise
-21.03%
-11.5%
5.04%
-2.54%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for aTyr Pharma stock?

aTyr Pharma (LIFE) has a market cap of $124M as of May 30, 2024.

What is the P/E ratio for aTyr Pharma stock?

The price to earnings (P/E) ratio for aTyr Pharma (LIFE) stock is 0 as of May 30, 2024.

Does aTyr Pharma stock pay dividends?

No, aTyr Pharma (LIFE) stock does not pay dividends to its shareholders as of May 30, 2024.

When is the next aTyr Pharma dividend payment date?

aTyr Pharma (LIFE) stock does not pay dividends to its shareholders.

What is the beta indicator for aTyr Pharma?

aTyr Pharma (LIFE) has a beta rating of 1.2. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

What is the aTyr Pharma stock price target?

The target price for aTyr Pharma (LIFE) stock is $24.6, which is 1313.79% above the current price of $1.74. This is an average based on projections from 5 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell aTyr Pharma stock

Buy or sell aTyr Pharma stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing